ARTICLE | Regulation
FDA panel for mRNA-1273 highlights challenges ahead for COVID vaccine trial recruitment, retention
December 18, 2020 3:24 AM UTC
The discussion at Thursday’s FDA advisory committee meeting on a COVID-19 vaccine from Moderna and NIH highlighted the increasing difficulties of conducting trials as more vaccines become authorized and widely available.
Out of the committee’s 21 voting members, 20 voted that the benefits of mRNA-1273 from Moderna Inc. (NASDAQ:MRNA) outweigh its risks for use in individuals 18 years of age and older. ...